The Role of Apolipoprotein E in Alzheimer's Disease

Neuron

Volumn 63, Issue 3, 2009, Pages 287-303

  Kim, Jungsu ^a   Basak, Jacob M ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN D; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; BETA2 GLYCOPROTEIN 1; CLUSTERIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN METABOLISM; COGNITION; DISEASE COURSE; GENE MUTATION; GENETIC RISK; GENOTYPE; HUMAN; INFLAMMATION; NERVE CELL PLASTICITY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEINS E; BRAIN; HUMANS; MICE; MODELS, BIOLOGICAL; MUTATION;

EID: 68249134074     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2009.06.026     Document Type: Review

References (241)

1. Aleshkov S., Abraham C.R., and Zannis V.I. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. Biochemistry 36 (1997) 10571-10580
2. Alexander G.E., Chen K., Pietrini P., Rapoport S.I., and Reiman E.M. Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer's disease treatment studies. Am. J. Psychiatry 159 (2002) 738-745
3. Andersen O.M., Reiche J., Schmidt V., Gotthardt M., Spoelgen R., Behlke J., von Arnim C.A., Breiderhoff T., Jansen P., Wu X., et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. USA 102 (2005) 13461-13466
4. Anderson R., Barnes J.C., Bliss T.V., Cain D.P., Cambon K., Davies H.A., Errington M.L., Fellows L.A., Gray R.A., Hoh T., et al. Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse. Neuroscience 85 (1998) 93-110
5. Arendt T., Schindler C., Bruckner M.K., Eschrich K., Bigl V., Zedlick D., and Marcova L. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J. Neurosci. 17 (1997) 516-529
6. Asada T., Kariya T., Yamagata Z., Kinoshita T., and Asaka A. ApoE epsilon 4 allele and cognitive decline in patients with Alzheimer's disease. Neurology 47 (1996) 603
7. Bales K.R., Verina T., Dodel R.C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E.M., Little S.P., Cummins D.J., et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17 (1997) 263-264
8. Bales K.R., Verina T., Cummins D.J., Du Y., Dodel R.C., Saura J., Fishman C.E., DeLong C.A., Piccardo P., Petegnief V., et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 96 (1999) 15233-15238
9. Bales K.R., Du Y., Holtzman D., Cordell B., and Paul S.M. Neuroinflammation and Alzheimer's disease: critical roles for cytokine/Abeta-induced glial activation, NF-kappaB, and apolipoprotein E. Neurobiol. Aging 21 (2000) 427-432
10. Bales K.R., Liu F., Wu S., Lin S., Koger D., DeLong C., Hansen J.C., Sullivan P.M., and Paul S.M. Human APOE Isoform-Dependent Effects on Brain {beta}-Amyloid Levels in PDAPP Transgenic Mice. J. Neurosci. 29 (2009) 6771-6779
11. Barger S.W., and Harmon A.D. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388 (1997) 878-881
12. Beffert U., and Poirier J. ApoE associated with lipid has a reduced capacity to inhibit beta-amyloid fibril formation. Neuroreport 9 (1998) 3321-3323
13. Beffert U., Aumont N., Dea D., Lussier-Cacan S., Davignon J., and Poirier J. Beta-amyloid peptides increase the binding and internalization of apolipoprotein E to hippocampal neurons. J. Neurochem. 70 (1998) 1458-1466
14. Beffert U., Aumont N., Dea D., Lussier-Cacan S., Davignon J., and Poirier J. Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Brain Res. Mol. Brain Res. 68 (1999) 181-185
15. Beffert U., Cohn J.S., Petit-Turcotte C., Tremblay M., Aumont N., Ramassamy C., Davignon J., and Poirier J. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res. 843 (1999) 87-94
16. Bekris L.M., Millard S.P., Galloway N.M., Vuletic S., Albers J.J., Li G., Galasko D.R., DeCarli C., Farlow M.R., Clark C.M., et al. Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J. Alzheimers Dis. 13 (2008) 255-266
17. Bell R.D., Sagare A.P., Friedman A.E., Bedi G.S., Holtzman D.M., Deane R., and Zlokovic B.V. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 27 (2007) 909-918
18. Bellosta S., Nathan B.P., Orth M., Dong L.M., Mahley R.W., and Pitas R.E. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J. Biol. Chem. 270 (1995) 27063-27071
19. Benjamin R., Leake A., Ince P.G., Perry R.H., McKeith I.G., Edwardson J.A., and Morris C.M. Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body and Alzheimer's disease. Neurodegeneration 4 (1995) 443-448
20. Bentahir M., Nyabi O., Verhamme J., Tolia A., Horre K., Wiltfang J., Esselmann H., and De Strooper B. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J. Neurochem. 96 (2006) 732-742
21. Berlau D.J., Corrada M.M., Head E., and Kawas C.H. APOE {varepsilon}2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology 72 (2009) 829-834
22. Bertram L., McQueen M.B., Mullin K., Blacker D., and Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39 (2007) 17-23
23. Bertram L., McQueen M.B., Mullin K., Blacker D., and Tanzi R.E. The AlzGene Database (2009), Alzheimer Research Forum. http://www.alzgene.org
24. Bertrand P., Poirier J., Oda T., Finch C.E., and Pasinetti G.M. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res. Mol. Brain Res. 33 (1995) 174-178
25. Biere A.L., Ostaszewski B., Zhao H., Gillespie S., Younkin S.G., and Selkoe D.J. Co-expression of beta-amyloid precursor protein (betaAPP) and apolipoprotein E in cell culture: analysis of betaAPP processing. Neurobiol. Dis. 2 (1995) 177-187
26. Blacklow S.C. Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers. Curr. Opin. Struct. Biol. 17 (2007) 418-426
27. Bodzioch M., Orso E., Klucken J., Langmann T., Bottcher A., Diederich W., Drobnik W., Barlage S., Buchler C., Porsch-Ozcurumez M., et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22 (1999) 347-351
28. Bour A., Grootendorst J., Vogel E., Kelche C., Dodart J.C., Bales K., Moreau P.H., Sullivan P.M., and Mathis C. Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. Behav. Brain Res. 193 (2008) 174-182
29. Bray N.J., Jehu L., Moskvina V., Buxbaum J.D., Dracheva S., Haroutunian V., Williams J., Buckland P.R., Owen M.J., and O'Donovan M.C. Allelic expression of APOE in human brain: Effects of epsilon status and promoter haplotypes. Hum. Mol. Genet. 13 (2004) 2885-2892
30. Brooks-Wilson A., Marcil M., Clee S.M., Zhang L.H., Roomp K., van Dam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O., et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22 (1999) 336-345
31. Brown M.S., and Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 232 (1986) 34-47
32. Buttini M., Yu G.Q., Shockley K., Huang Y., Jones B., Masliah E., Mallory M., Yeo T., Longo F.M., and Mucke L. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. J. Neurosci. 22 (2002) 10539-10548
33. Cam J.A., and Bu G. Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol. Neurodegener. 1 (2006) 8
34. Cambon K., Davies H.A., and Stewart M.G. Synaptic loss is accompanied by an increase in synaptic area in the dentate gyrus of aged human apolipoprotein E4 transgenic mice. Neuroscience 97 (2000) 685-692
35. Cao D., Fukuchi K., Wan H., Kim H., and Li L. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol. Aging 27 (2006) 1632-1643
36. Castano E.M., Prelli F., Wisniewski T., Golabek A., Kumar R.A., Soto C., and Frangione B. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem. J. 306 (1995) 599-604
37. Cedazo-Minguez A., Wiehager B., Winblad B., Huttinger M., and Cowburn R.F. Effects of apolipoprotein E (apoE) isoforms, beta-amyloid (Abeta) and apoE/Abeta complexes on protein kinase C-alpha (PKC-alpha) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts. Neurochem. Int. 38 (2001) 615-625
38. Chang S., ran Ma T., Miranda R.D., Balestra M.E., Mahley R.W., and Huang Y. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc. Natl. Acad. Sci. USA 102 (2005) 18694-18699
39. Charnay Y., Imhof A., Vallet P.G., Hakkoum D., Lathuiliere A., Poku N., Aronow B., Kovari E., Bouras C., and Giannakopoulos P. Clusterin expression during fetal and postnatal CNS development in mouse. Neuroscience 155 (2008) 714-724
40. Cirrito J.R., Deane R., Fagan A.M., Spinner M.L., Parsadanian M., Finn M.B., Jiang H., Prior J.L., Sagare A., Bales K.R., et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest. 115 (2005) 3285-3290
41. Cirrito J.R., Kang J.E., Lee J., Stewart F.R., Verges D.K., Silverio L.M., Bu G., Mennerick S., and Holtzman D.M. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 58 (2008) 42-51
42. Cole G.M., and Ard M.D. Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein. Microsc. Res. Tech. 50 (2000) 316-324
43. Colton C.A., Needham L.K., Brown C., Cook D., Rasheed K., Burke J.R., Strittmatter W.J., Schmechel D.E., and Vitek M.P. APOE genotype-specific differences in human and mouse macrophage nitric oxide production. J. Neuroimmunol. 147 (2004) 62-67
44. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
45. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell Jr. P.C., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7 (1994) 180-184
46. Cosentino S., Scarmeas N., Helzner E., Glymour M.M., Brandt J., Albert M., Blacker D., and Stern Y. APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology 70 (2008) 1842-1849
47. Craft S., Teri L., Edland S.D., Kukull W.A., Schellenberg G., McCormick W.C., Bowen J.D., and Larson E.B. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology 51 (1998) 149-153
48. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M.B., Holtzman D.M., and Zlokovic B.V. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118 (2008) 4002-4013
49. DeMattos R.B. Apolipoprotein E dose-dependent modulation of beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. J. Mol. Neurosci. 23 (2004) 255-262
50. DeMattos R.B., Curtiss L.K., and Williams D.L. A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins. J. Biol. Chem. 273 (1998) 4206-4212
51. DeMattos R.B., Thorngate F.E., and Williams D.L. A test of the cytosolic apolipoprotein E hypothesis fails to detect the escape of apolipoprotein E from the endocytic pathway into the cytosol and shows that direct expression of apolipoprotein E in the cytosol is cytotoxic. J. Neurosci. 19 (1999) 2464-2473
52. DeMattos R.B., O'Dell M.A., Parsadanian M., Taylor J.W., Harmony J.A., Bales K.R., Paul S.M., Aronow B.J., and Holtzman D.M. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 99 (2002) 10843-10848
53. DeMattos R.B., Cirrito J.R., Parsadanian M., May P.C., O'Dell M.A., Taylor J.W., Harmony J.A., Aronow B.J., Bales K.R., Paul S.M., and Holtzman D.M. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 41 (2004) 193-202
54. Dergunov A.D., Smirnova E.A., Merched A., Visvikis S., Siest G., Yakushkin V.V., and Tsibulsky V. Conformation of apolipoprotein E both in free and in lipid-bound form may determine the avidity of triglyceride-rich lipoproteins to the LDL receptor: structural and kinetic study. Biochim. Biophys. Acta 1484 (2000) 14-28
55. Dodart J.C., Bales K.R., Johnstone E.M., Little S.P., and Paul S.M. Apolipoprotein E alters the processing of the beta-amyloid precursor protein in APP(V717F) transgenic mice. Brain Res. 955 (2002) 191-199
56. Dodart J.C., Marr R.A., Koistinaho M., Gregersen B.M., Malkani S., Verma I.M., and Paul S.M. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 102 (2005) 1211-1216
57. Dodson S.E., Andersen O.M., Karmali V., Fritz J.J., Cheng D., Peng J., Levey A.I., Willnow T.E., and Lah J.J. Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: Evidence for a proximal role in Alzheimer's disease. J. Neurosci. 28 (2008) 12877-12886
58. Dolev I., and Michaelson D.M. A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. Proc. Natl. Acad. Sci. USA 101 (2004) 13909-13914
59. Elosua R., Ordovas J.M., Cupples L.A., Fox C.S., Polak J.F., Wolf P.A., D'Agostino Sr. R.A., and O'Donnell C.J. Association of APOE genotype with carotid atherosclerosis in men and women: the Framingham Heart Study. J. Lipid Res. 45 (2004) 1868-1875
60. Evans K.C., Berger E.P., Cho C.G., Weisgraber K.H., and Lansbury Jr. P.T. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc. Natl. Acad. Sci. USA 92 (1995) 763-767
61. Fagan A.M., Bu G., Sun Y., Daugherty A., and Holtzman D.M. Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J. Biol. Chem. 271 (1996) 30121-30125
62. Fagan A.M., Murphy B.A., Patel S.N., Kilbridge J.F., Mobley W.C., Bu G., and Holtzman D.M. Evidence for normal aging of the septo-hippocampal cholinergic system in apoE (-/-) mice but impaired clearance of axonal degeneration products following injury. Exp. Neurol. 151 (1998) 314-325
63. Fagan A.M., Holtzman D.M., Munson G., Mathur T., Schneider D., Chang L.K., Getz G.S., Reardon C.A., Lukens J., Shah J.A., and LaDu M.J. Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. J. Biol. Chem. 274 (1999) 30001-30007
64. Fagan A.M., Watson M., Parsadanian M., Bales K.R., Paul S.M., and Holtzman D.M. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9 (2002) 305-318
65. Fagan A.M., Christopher E., Taylor J.W., Parsadanian M., Spinner M., Watson M., Fryer J.D., Wahrle S., Bales K.R., Paul S.M., and Holtzman D.M. ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. Am. J. Pathol. 165 (2004) 1413-1422
66. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 59 (2006) 512-519
67. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., and van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. J. Am. Med. Assoc. 278 (1997) 1349-1356
68. Frisoni G.B., Govoni S., Geroldi C., Bianchetti A., Calabresi L., Franceschini G., and Trabucchi M. Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann. Neurol. 37 (1995) 596-604
69. Fryer J.D., Demattos R.B., McCormick L.M., O'Dell M.A., Spinner M.L., Bales K.R., Paul S.M., Sullivan P.M., Parsadanian M., Bu G., and Holtzman D.M. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J. Biol. Chem. 280 (2005) 25754-25759
70. Fryer J.D., Simmons K., Parsadanian M., Bales K.R., Paul S.M., Sullivan P.M., and Holtzman D.M. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J. Neurosci. 25 (2005) 2803-2810
71. Fuentealba R.A., Barria M.I., Lee J., Cam J., Araya C., Escudero C.A., Inestrosa N.C., Bronfman F.C., Bu G., and Marzolo M.P. ApoER2 expression increases Abeta production while decreasing Amyloid Precursor Protein (APP)endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of gamma-secretase activity. Mol. Neurodegener. 2 (2007) 14
72. Fukumoto H., Ingelsson M., Garevik N., Wahlund L.O., Nukina N., Yaguchi Y., Shibata M., Hyman B.T., Rebeck G.W., and Irizarry M.C. APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. Exp. Neurol. 183 (2003) 249-253
73. Gatz M., Reynolds C.A., Fratiglioni L., Johansson B., Mortimer J.A., Berg S., Fiske A., and Pedersen N.L. Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry 63 (2006) 168-174
74. Gearing M., Mori H., and Mirra S.S. Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann. Neurol. 39 (1996) 395-399
75. Ghebremedhin E., Schultz C., Braak E., and Braak H. High frequency of apolipoprotein E epsilon4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Exp. Neurol. 153 (1998) 152-155
76. Ghiso J., Matsubara E., Koudinov A., Choi-Miura N.H., Tomita M., Wisniewski T., and Frangione B. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J. 293 (1993) 27-30
77. Gomez-Isla T., West H.L., Rebeck G.W., Harr S.D., Growdon J.H., Locascio J.J., Perls T.T., Lipsitz L.A., and Hyman B.T. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann. Neurol. 39 (1996) 62-70
78. Graner M., Kahri J., Varpula M., Salonen R.M., Nyyssonen K., Jauhiainen M., Nieminen M.S., Syvanne M., and Taskinen M.R. Apolipoprotein E polymorphism is associated with both carotid and coronary atherosclerosis in patients with coronary artery disease. Nutr. Metab. Cardiovasc. Dis. 18 (2008) 271-277
79. Grehan S., Tse E., and Taylor J.M. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J. Neurosci. 21 (2001) 812-822
80. Grootendorst J., Bour A., Vogel E., Kelche C., Sullivan P.M., Dodart J.-C., Bales K., and Mathis C. Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior. Behav. Brain Res. 159 (2005) 1-14
81. Growdon J.H., Locascio J.J., Corkin S., Gomez-Isla T., and Hyman B.T. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 47 (1996) 444-448
82. Growdon W.B., Cheung B.S., Hyman B.T., and Rebeck G.W. Lack of allelic imbalance in APOE epsilon3/4 brain mRNA expression in Alzheimer's disease. Neurosci. Lett. 272 (1999) 83-86
83. Guo L., LaDu M.J., and Van Eldik L.J. A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity. J. Mol. Neurosci. 23 (2004) 205-212
84. Haass C., and Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8 (2007) 101-112
85. Hamanaka H., Katoh-Fukui Y., Suzuki K., Kobayashi M., Suzuki R., Motegi Y., Nakahara Y., Takeshita A., Kawai M., Ishiguro K., et al. Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice. Hum. Mol. Genet. 9 (2000) 353-361
86. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics. Science 297 (2002) 353-356
87. Harr S.D., Uint L., Hollister R., Hyman B.T., and Mendez A.J. Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J. Neurochem. 66 (1996) 2429-2435
88. Harris F.M., Brecht W.J., Xu Q., Mahley R.W., and Huang Y. Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc. J. Biol. Chem. 279 (2004) 44795-44801
89. Hartman R.E., Wozniak D.F., Nardi A., Olney J.W., Sartorius L., and Holtzman D.M. Behavioral phenotyping of GFAP-ApoE3 and -ApoE4 transgenic mice: ApoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology. Exp. Neurol. 170 (2001) 326-344
90. He X., Cooley K., Chung C.H.Y., Dashti N., and Tang J. Apolipoprotein receptor 2 and X11/β mediate apolipoprotein E-induced endocytosis of amyloid-β precursor protein and β-secretase, leading to amyloid-β production. J. Neurosci. 27 (2007) 4052-4060
91. Heinonen O., Lehtovirta M., Soininen H., Helisalmi S., Mannermaa A., Sorvari H., Kosunen O., Paljarvi L., Ryynanen M., and Riekkinen Sr. P.J. Alzheimer pathology of patients carrying apolipoprotein E epsilon 4 allele. Neurobiol. Aging 16 (1995) 505-513
92. Herz J., and Bock H.H. Lipoprotein receptors in the nervous system. Annu. Rev. Biochem. 71 (2002) 405-434
93. Herz J., and Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat. Rev. Neurosci. 7 (2006) 850-859
94. Hirsch-Reinshagen V., Zhou S., Burgess B.L., Bernier L., McIsaac S.A., Chan J.Y., Tansley G.H., Cohn J.S., Hayden M.R., and Wellington C.L. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J. Biol. Chem. 279 (2004) 41197-41207
95. Hirsch-Reinshagen V., Maia L.F., Burgess B.L., Blain J.F., Naus K.E., McIsaac S.A., Parkinson P.F., Chan J.Y., Tansley G.H., Hayden M.R., et al. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J. Biol. Chem. 280 (2005) 43243-43256
96. Ho A., and Sudhof T.C. Binding of F-spondin to amyloid-{beta} precursor protein: A candidate amyloid-{beta} precursor protein ligand that modulates amyloid-{beta} precursor protein cleavage. Proc. Natl. Acad. Sci. USA 101 (2004) 2548-2553
97. Hoe H.S., Harris D.C., and Rebeck G.W. Multiple pathways of apolipoprotein E signaling in primary neurons. J. Neurochem. 93 (2005) 145-155
98. Hoe H.S., Wessner D., Beffert U., Becker A.G., Matsuoka Y., and Rebeck G.W. F-spondin interaction with the apolipoprotein E receptor ApoEr2 affects processing of amyloid precursor protein. Mol. Cell. Biol. 25 (2005) 9259-9268
99. Holtzman D.M., Pitas R.E., Kilbridge J., Nathan B., Mahley R.W., Bu G., and Schwartz A.L. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc. Natl. Acad. Sci. USA 92 (1995) 9480-9484
100. Holtzman D.M., Bales K.R., Wu S., Bhat P., Parsadanian M., Fagan A.M., Chang L.K., Sun Y., and Paul S.M. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 103 (1999) R15-R21
101. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., Mackey B., Olney J., McKeel D., Wozniak D., and Paul S.M. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97 (2000) 2892-2897
102. Hoyt B.D., Massman P.J., Schatschneider C., Cooke N., and Doody R.S. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch. Neurol. 62 (2005) 454-459
103. Hu J., Akama K.T., Krafft G.A., Chromy B.A., and Van Eldik L.J. Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res. 785 (1998) 195-206
104. Irizarry M.C., Cheung B.S., Rebeck G.W., Paul S.M., Bales K.R., and Hyman B.T. Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP(V717F) transgenic mice. Acta Neuropathol. (Berl.) 100 (2000) 451-458
105. Irizarry M.C., Deng A., Lleo A., Berezovska O., Von Arnim C.A., Martin-Rehrmann M., Manelli A., LaDu M.J., Hyman B.T., and Rebeck G.W. Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. J. Neurochem. 90 (2004) 1132-1143
106. Ishii K., Tamaoka A., Mizusawa H., Shoji S., Ohtake T., Fraser P.E., Takahashi H., Tsuji S., Gearing M., Mizutani T., et al. Abeta1-40 but not Abeta1-42 levels in cortex correlate with apolipoprotein E epsilon4 allele dosage in sporadic Alzheimer's disease. Brain Res. 748 (1997) 250-252
107. Ito S., Ohtsuki S., Kamiie J., Nezu Y., and Terasaki T. Cerebral clearance of human amyloid-beta peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes. J. Neurochem. 103 (2007) 2482-2490
108. Itoh Y., and Yamada M. Apolipoprotein E and the neuropathology of dementia. N. Engl. J. Med. 334 (1996) 599-600
109. Jacobsen L., Madsen P., Moestrup S.K., Lund A.H., Tommerup N., Nykjaer A., Sottrup-Jensen L., Gliemann J., and Petersen C.M. Molecular characterization of a novel human hybrid-type receptor that binds the alpha2-macroglobulin receptor-associated protein. J. Biol. Chem. 271 (1996) 31379-31383
110. Ji Y., Permanne B., Sigurdsson E.M., Holtzman D.M., and Wisniewski T. Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. J. Alzheimers Dis. 3 (2001) 23-30
111. Jiang Q., Lee C.Y., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Willson T.M., Collins J.L., et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 58 (2008) 681-693
112. Juva K., Verkkoniemi A., Viramo P., Polvikoski T., Kainulainen K., Kontula K., and Sulkava R. APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old. Neurology 54 (2000) 412-415
113. Kalaria R.N., Maestre G.E., Arizaga R., Friedland R.P., Galasko D., Hall K., Luchsinger J.A., Ogunniyi A., Perry E.K., Potocnik F., et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 7 (2008) 812-826
114. Kim J., Onstead L., Randle S., Price R., Smithson L., Zwizinski C., Dickson D.W., Golde T., and McGowan E. Abeta40 inhibits amyloid deposition in vivo. J. Neurosci. 27 (2007) 627-633
115. Koistinaho M., Lin S., Wu X., Esterman M., Koger D., Hanson J., Higgs R., Liu F., Malkani S., Bales K.R., and Paul S.M. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat. Med. 10 (2004) 719-726
116. Koldamova R.P., Lefterov I.M., Lefterova M.I., and Lazo J.S. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 40 (2001) 3553-3560
117. Koldamova R., Staufenbiel M., and Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 280 (2005) 43224-43235
118. Koo E.H., and Squazzo S.L. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269 (1994) 17386-17389
119. Kurz A., Egensperger R., Haupt M., Lautenschlager N., Romero B., Graeber M.B., and Muller U. Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology 47 (1996) 440-443
120. LaDu M.J., Falduto M.T., Manelli A.M., Reardon C.A., Getz G.S., and Frail D.E. Isoform-specific binding of apolipoprotein E to beta-amyloid. J. Biol. Chem. 269 (1994) 23403-23406
121. Ladu M.J., Reardon C., Van Eldik L., Fagan A.M., Bu G., Holtzman D., and Getz G.S. Lipoproteins in the central nervous system. Ann. N Y Acad. Sci. 903 (2000) 167-175
122. LaDu M.J., Shah J.A., Reardon C.A., Getz G.S., Bu G., Hu J., Guo L., and van Eldik L.J. Apolipoprotein E receptors mediate the effects of beta-amyloid on astrocyte cultures. J. Biol. Chem. 275 (2000) 33974-33980
123. LaDu M.J., Shah J.A., Reardon C.A., Getz G.S., Bu G., Hu J., Guo L., and Van Eldik L.J. Apolipoprotein E and apolipoprotein E receptors modulate A beta-induced glial neuroinflammatory responses. Neurochem. Int. 39 (2001) 427-434
124. Lambert J.C., Perez-Tur J., Dupire M.J., Galasko D., Mann D., Amouyel P., Hardy J., Delacourte A., and Chartier-Harlin M.C. Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. Hum. Mol. Genet. 6 (1997) 2151-2154
125. Lämsä R., Helisalmi S., Herukka S.K., Tapiola T., Pirttilä T., Vepsäläinen S., Hiltunen M., and Soininen H. Genetic study evaluating LDLR polymorphisms and Alzheimer's disease. Neurobiol. Aging 29 (2008) 848-855
126. Landen M., Hesse C., Fredman P., Regland B., Wallin A., and Blennow K. Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform. Dementia 7 (1996) 273-278
127. Landen M., Thorsell A., Wallin A., and Blennow K. The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 61 (1996) 352-356
128. Lanz T.A., Carter D.B., and Merchant K.M. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol. Dis. 13 (2003) 246-253
129. Lawn R.M., Wade D.P., Garvin M.R., Wang X., Schwartz K., Porter J.G., Seilhamer J.J., Vaughan A.M., and Oram J.F. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J. Clin. Invest. 104 (1999) R25-R31
130. Lefranc D., Vermersch P., Dallongeville J., Daems-Monpeurt C., Petit H., and Delacourte A. Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease. Neurosci. Lett. 212 (1996) 91-94
131. Lehtimaki T., Pirttila T., Mehta P.D., Wisniewski H.M., Frey H., and Nikkari T. Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum. Genet. 95 (1995) 39-42
132. Lindh M., Blomberg M., Jensen M., Basun H., Lannfelt L., Engvall B., Scharnagel H., Marz W., Wahlund L.O., and Cowburn R.F. Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci. Lett. 229 (1997) 85-88
133. Liu Q., Zerbinatti C.V., Zhang J., Hoe H.-S., Wang B., Cole S.L., Herz J., Muglia L., and Bu G. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56 (2007) 66-78
134. Ljungberg M.C., Asuni A., Pearce J., Dayanandan R., Marz W., Hoffmann M.M., Bertrand P., Siest G., Rupniak H.T., Anderton B.H., et al. Apolipoprotein E (apoE) uptake and distribution in mammalian cell lines is dependent upon source of apoE and can be monitored in living cells. Neurosci. Lett. 341 (2003) 69-73
135. Lynch J.R., Morgan D., Mance J., Matthew W.D., and Laskowitz D.T. Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J. Neuroimmunol. 114 (2001) 107-113
136. Lynch J.R., Tang W., Wang H., Vitek M.P., Bennett E.R., Sullivan P.M., Warner D.S., and Laskowitz D.T. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J. Biol. Chem. 278 (2003) 48529-48533
137. Ma J., Yee A., Brewer Jr. H.B., Das S., and Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372 (1994) 92-94
138. Ma J., Brewer Jr. H.B., and Potter H. Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. Neurobiol. Aging 17 (1996) 773-780
139. Mahley R.W., and Rall Jr. S.C. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1 (2000) 507-537
140. Mahley R.W., Weisgraber K.H., and Huang Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. USA 103 (2006) 5644-5651
141. Mahley R.W., Huang Y., and Weisgraber K.H. Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 4 (2007) 537-540
142. Mann D.M., Iwatsubo T., Pickering-Brown S.M., Owen F., Saido T.C., and Perry R.H. Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Neurosci. Lett. 221 (1997) 81-84
143. Mann K.M., Thorngate F.E., Katoh-Fukui Y., Hamanaka H., Williams D.L., Fujita S., and Lamb B.T. Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model. Hum. Mol. Genet. 13 (2004) 1959-1968
144. Martel C.L., Mackic J.B., Matsubara E., Governale S., Miguel C., Miao W., McComb J.G., Frangione B., Ghiso J., and Zlokovic B.V. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. J. Neurochem. 69 (1997) 1995-2004
145. Masliah E., Samuel W., Veinbergs I., Mallory M., Mante M., and Saitoh T. Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Brain Res. 751 (1997) 307-314
146. Mayeux R. Apolipoprotein E, Alzheimer disease, and African Americans. Arch. Neurol. 60 (2003) 161-163
147. McGowan E., Pickford F., Kim J., Onstead L., Eriksen J., Yu C., Skipper L., Murphy M.P., Beard J., Das P., et al. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47 (2005) 191-199
148. Minoshima S., Frey K.A., Koeppe R.A., Foster N.L., and Kuhl D.E. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J. Nucl. Med. 36 (1995) 1238-1248
149. Mooijaart S.P., Berbée J.F.P., Van Heemst D., Havekes L.M., De Craen A.J.M., Slagboom P.E., Rensen P.C.N., and Westendorp R.G.J. ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Medicine 3 (2006) 0874-0883
150. Morris C.M., Benjamin R., Leake A., McArthur F.K., Candy J.M., Ince P.G., Torvik A., Bjertness E., and Edwardson J.A. Effect of apolipoprotein E genotype on Alzheimer's disease neuropathology in a cohort of elderly Norwegians. Neurosci. Lett. 201 (1995) 45-47
151. Motoi Y., Aizawa T., Haga S., Nakamura S., Namba Y., and Ikeda K. Neuronal localization of a novel mosaic apolipoprotein E receptor, LR11, in rat and human brain. Brain Res. 833 (1999) 209-215
152. Mulder M., Ravid R., Swaab D.F., de Kloet E.R., Haasdijk E.D., Julk J., van der Boom J.J., and Havekes L.M. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis. Assoc. Disord. 12 (1998) 198-203
153. Nagy Z., Esiri M.M., Jobst K.A., Johnston C., Litchfield S., Sim E., and Smith A.D. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 69 (1995) 757-761
154. Namba Y., Tomonaga M., Kawasaki H., Otomo E., and Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541 (1991) 163-166
155. Narita M., Bu G., Holtzman D.M., and Schwartz A.L. The low-density lipoprotein receptor-related protein, a multifunctional apolipoprotein E receptor, modulates hippocampal neurite development. J. Neurochem. 68 (1997) 587-595
156. Naslund J., Thyberg J., Tjernberg L.O., Wernstedt C., Karlstrom A.R., Bogdanovic N., Gandy S.E., Lannfelt L., Terenius L., and Nordstedt C. Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain. Neuron 15 (1995) 219-228
157. Nathan B.P., Bellosta S., Sanan D.A., Weisgraber K.H., Mahley R.W., and Pitas R.E. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264 (1994) 850-852
158. Nathan B.P., Chang K.C., Bellosta S., Brisch E., Ge N., Mahley R.W., and Pitas R.E. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J. Biol. Chem. 270 (1995) 19791-19799
159. Nathan B.P., Jiang Y., Wong G.K., Shen F., Brewer G.J., and Struble R.G. Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein. Brain Res. 928 (2002) 96-105
160. Nickerson D.A., Taylor S.L., Fullerton S.M., Weiss K.M., Clark A.G., Stengard J.H., Salomaa V., Boerwinkle E., and Sing C.F. Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene. Genome Res. 10 (2000) 1532-1545
161. Nielsen H.M., Veerhuis R., Holmqvist B., and Janciauskiene S. Binding and uptake of Abeta1-42 by primary human astrocytes in vitro. Glia 57 (2008) 978-988
162. Ohm T.G., Kirca M., Bohl J., Scharnagl H., Gross W., and Marz W. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 66 (1995) 583-587
163. Olichney J.M., Hansen L.A., Galasko D., Saitoh T., Hofstetter C.R., Katzman R., and Thal L.J. The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology 47 (1996) 190-196
164. Oyama F., Shimada H., Oyama R., and Ihara Y. Apolipoprotein E genotype, Alzheimer's pathologies and related gene expression in the aged population. Brain Res. Mol. Brain Res. 29 (1995) 92-98
165. Paula-Lima A.C., Tricerri M.A., Brito-Moreira J., Bomfim T.R., Oliveira F.F., Magdesian M.H., Grinberg L.T., Panizzutti R., and Ferreira S.T. Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity. Int. J. Biochem. Cell Biol. 41 (2009) 1361-1370
166. Pfrieger F.W. Cholesterol homeostasis and function in neurons of the central nervous system. Cell. Mol. Life Sci. 60 (2003) 1158-1171
167. Pirttila T., Soininen H., Heinonen O., Lehtimaki T., Bogdanovic N., Paljarvi L., Kosunen O., Winblad B., Riekkinen Sr. P., Wisniewski H.M., and Mehta P.D. Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls. Brain Res. 722 (1996) 71-77
168. Pitas R.E., Boyles J.K., Lee S.H., Hui D., and Weisgraber K.H. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J. Biol. Chem. 262 (1987) 14352-14360
169. Polvikoski T., Sulkava R., Haltia M., Kainulainen K., Vuorio A., Verkkoniemi A., Niinisto L., Halonen P., and Kontula K. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N. Engl. J. Med. 333 (1995) 1242-1247
170. Puttfarcken P.S., Manelli A.M., Falduto M.T., Getz G.S., and LaDu M.J. Effect of apolipoprotein E on neurite outgrowth and beta-amyloid-induced toxicity in developing rat primary hippocampal cultures. J. Neurochem. 68 (1997) 760-769
171. Raber J., Wong D., Buttini M., Orth M., Bellosta S., Pitas R.E., Mahley R.W., and Mucke L. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc. Natl. Acad. Sci. USA 95 (1998) 10914-10919
172. Raber J., Wong D., Yu G.Q., Buttini M., Mahley R.W., Pitas R.E., and Mucke L. Apolipoprotein E and cognitive performance. Nature 404 (2000) 352-354
173. Ramaswamy G., Xu Q., Huang Y., and Weisgraber K.H. Effect of domain interaction on apolipoprotein E levels in mouse brain. J. Neurosci. 25 (2005) 10658-10663
174. Rebeck G.W., Reiter J.S., Strickland D.K., and Hyman B.T. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11 (1993) 575-580
175. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Thibodeau S.N., and Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N. Engl. J. Med. 334 (1996) 752-758
176. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., and Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. USA 101 (2004) 284-289
177. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., and Hardy J. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc. Natl. Acad. Sci. USA 102 (2005) 8299-8302
178. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S.A., Langbaum J.B., et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 106 (2009) 6820-6825
179. Rensen P.C., Jong M.C., van Vark L.C., van der Boom H., Hendriks W.L., van Berkel T.J., Biessen E.A., and Havekes L.M. Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J. Biol. Chem. 275 (2000) 8564-8571
180. Riddell D.R., Zhou H., Atchison K., Warwick H.K., Atkinson P.J., Jefferson J., Xu L., Aschmies S., Kirksey Y., Hu Y., et al. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J. Neurosci. 28 (2008) 11445-11453
181. Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., Katayama T., Baldwin C.T., Cheng R., Hasegawa H., et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 39 (2007) 168-177
182. Roses A.D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47 (1996) 387-400
183. Ruiz J., Kouiavskaia D., Migliorini M., Robinson S., Saenko E.L., Gorlatova N., Li D., Lawrence D., Hyman B.T., Weisgraber K.H., and Strickland D.K. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J. Lipid Res. 46 (2005) 1721-1731
184. Rust S., Rosier M., Funke H., Real J., Amoura Z., Piette J.C., Deleuze J.F., Brewer H.B., Duverger N., Denefle P., and Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22 (1999) 352-355
185. Sadowski M.J., Pankiewicz J., Scholtzova H., Mehta P.D., Prelli F., Quartermain D., and Wisniewski T. Blocking the apolipoprotein E/amyloid-{beta} interaction as a potential therapeutic approach for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 103 (2006) 18787-18792
186. Sager K.L., Wuu J., Leurgans S.E., Rees H.D., Gearing M., Mufson E.J., Levey A.I., and Lah J.J. Neuronal LR11/sorLA expression is reduced in mild cognitive impairment. Ann. Neurol. 62 (2007) 640-647
187. Sanan D.A., Weisgraber K.H., Russell S.J., Mahley R.W., Huang D., Saunders A., Schmechel D., Wisniewski T., Frangione B., Roses A.D., et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J. Clin. Invest. 94 (1994) 860-869
188. Scherzer C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I., and Lah J.J. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch. Neurol. 61 (2004) 1200-1205
189. Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., and Roses A.D. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90 (1993) 9649-9653
190. Schmidt V., Sporbert A., Rohe M., Reimer T., Rehm A., Andersen O.M., and Willnow T.E. SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1. J. Biol. Chem. 282 (2007) 32956-32964
191. Schonheit B., Glockner F., and Ohm T.G. Apolipoprotein E polymorphism and dendritic shape in hippocampal interneurons. Neurobiol. Aging 28 (2007) 677-686
192. Selkoe D.J. Clearing the brain's amyloid cobwebs. Neuron 32 (2001) 177-180
193. Shen J., and Kelleher III R.J. The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism. Proc. Natl. Acad. Sci. USA 104 (2007) 403-409
194. Sihlbom C., Davidsson P., Sjögren M., Wahlund L.-O., and Nilsson C. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals. Neurochem. Res. 33 (2008) 1332-1340
195. Slezak M., and Pfrieger F.W. New roles for astrocytes: regulation of CNS synaptogenesis. Trends Neurosci. 26 (2003) 531-535
196. Small G.W., Ercoli L.M., Silverman D.H., Huang S.C., Komo S., Bookheimer S.Y., Lavretsky H., Miller K., Siddarth P., Rasgon N.L., et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97 (2000) 6037-6042
197. Song Y., Stampfer M.J., and Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann. Intern. Med. 141 (2004) 137-147
198. Steiner H., and Haass C. Intramembrane proteolysis by presenilins. Nat. Rev. Mol. Cell Biol. 1 (2000) 217-224
199. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., and Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90 (1993) 1977-1981
200. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., and Roses A.D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90 (1993) 8098-8102
201. Strittmatter W.J., Saunders A.M., Goedert M., Weisgraber K.H., Dong L.M., Jakes R., Huang D.Y., Pericak-Vance M., Schmechel D., and Roses A.D. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc. Natl. Acad. Sci. USA 91 (1994) 11183-11186
202. Sullivan P.M., Mezdour H., Aratani Y., Knouff C., Najib J., Reddick R.L., Quarfordt S.H., and Maeda N. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 272 (1997) 17972-17980
203. *2. J. Clin. Invest. 102 (1998) 130-135
204. Sullivan P.M., Mace B.E., Maeda N., and Schmechel D.E. Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice. Neuroscience 124 (2004) 725-733
205. Sun Y., Wu S., Bu G., Onifade M.K., Patel S.N., LaDu M.J., Fagan A.M., and Holtzman D.M. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J. Neurosci. 18 (1998) 3261-3272
206. Sunderland T., Mirza N., Putnam K.T., Linker G., Bhupali D., Durham R., Soares H., Kimmel L., Friedman D., Bergeson J., et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol. Psychiatry 56 (2004) 670-676
207. Tamboli I.Y., Prager K., Thal D.R., Thelen K.M., Dewachter I., Pietrzik C.U., St. George-Hyslop P., Sisodia S.S., De Strooper B., Heneka M.T., et al. Loss of gamma-secretase function impairs endocytosis of lipoprotein particles and membrane cholesterol homeostasis. J. Neurosci. 28 (2008) 12097-12106
208. Tang M.X., Stern Y., Marder K., Bell K., Gurland B., Lantigua R., Andrews H., Feng L., Tycko B., and Mayeux R. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA 279 (1998) 751-755
209. Tanzi R.E., and Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120 (2005) 545-555
210. Teter B., Xu P.T., Gilbert J.R., Roses A.D., Galasko D., and Cole G.M. Human apolipoprotein E isoform-specific differences in neuronal sprouting in organotypic hippocampal culture. J. Neurochem. 73 (1999) 2613-2616
211. Teter B., Xu P.T., Gilbert J.R., Roses A.D., Galasko D., and Cole G.M. Defective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative function. J. Neurosci. Res. 68 (2002) 331-336
212. Tiraboschi P., Hansen L.A., Masliah E., Alford M., Thal L.J., and Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 62 (2004) 1977-1983
213. Tokuda T., Calero M., Matsubara E., Vidal R., Kumar A., Permanne B., Zlokovic B., Smith J.D., Ladu M.J., Rostagno A., et al. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem. J. 348 (2000) 359-365
214. Tolar M., Keller J.N., Chan S., Mattson M.P., Marques M.A., and Crutcher K.A. Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity. J. Neurosci. 19 (1999) 7100-7110
215. Trommer B.L., Shah C., Yun S.H., Gamkrelidze G., Pasternak E.S., Ye G.L., Sotak M., Sullivan P.M., Pasternak J.F., and LaDu M.J. ApoE isoform affects LTP in human targeted replacement mice. Neuroreport 15 (2004) 2655-2658
216. van den Elzen P., Garg S., Leon L., Brigl M., Leadbetter E.A., Gumperz J.E., Dascher C.C., Cheng T.Y., Sacks F.M., Illarionov P.A., et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437 (2005) 906-910
217. Veinbergs I., Mallory M., Mante M., Rockenstein E., Gilbert J.R., and Masliah E. Differential neurotrophic effects of apolipoprotein E in aged transgenic mice. Neurosci. Lett. 265 (1999) 218-222
218. Vitek M.P., Brown C.M., and Colton C.A. APOE genotype-specific differences in the innate immune response. Neurobiol. Aging 30 (2007) 1350-1360
219. Wahrle S.E., Jiang H., Parsadanian M., Legleiter J., Han X., Fryer J.D., Kowalewski T., and Holtzman D.M. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 279 (2004) 40987-40993
220. Wahrle S.E., Jiang H., Parsadanian M., Hartman R.E., Bales K.R., Paul S.M., and Holtzman D.M. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280 (2005) 43236-43242
221. Wahrle S.E., Shah A.R., Fagan A.M., Smemo S., Kauwe J.S., Grupe A., Hinrichs A., Mayo K., Jiang H., Thal L.J., et al. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol. Neurodegener. 2 (2007) 7
222. Wahrle S.E., Jiang H., Parsadanian M., Kim J., Li A., Knoten A., Jain S., Hirsch-Reinshagen V., Wellington C.L., Bales K.R., et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 118 (2008) 671-682
223. Wang C., Wilson W.A., Moore S.D., Mace B.E., Maeda N., Schmechel D.E., and Sullivan P.M. Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. Neurobiol. Dis. 18 (2005) 390-398
224. Webster S., and Rogers J. Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation. J. Neurosci. Res. 46 (1996) 58-66
225. Wernette-Hammond M.E., Lauer S.J., Corsini A., Walker D., Taylor J.M., and Rall Jr. S.C. Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194. J. Biol. Chem. 264 (1989) 9094-9101
226. White F., Nicoll J.A., Roses A.D., and Horsburgh K. Impaired neuronal plasticity in transgenic mice expressing human apolipoprotein E4 compared to E3 in a model of entorhinal cortex lesion. Neurobiol. Dis. 8 (2001) 611-625
227. Wilson P.W., Myers R.H., Larson M.G., Ordovas J.M., Wolf P.A., and Schaefer E.J. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 272 (1994) 1666-1671
228. Winklhofer K.F., Tatzelt J., and Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 27 (2008) 336-349
229. Wisniewski T., and Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135 (1992) 235-238
230. Wisniewski T., Castano E.M., Golabek A., Vogel T., and Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 145 (1994) 1030-1035
231. Wood S.J., Chan W., and Wetzel R. Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry 35 (1996) 12623-12628
232. Xu P.T., Schmechel D., Rothrock-Christian T., Burkhart D.S., Qiu H.L., Popko B., Sullivan P., Maeda N., Saunders A.M., Roses A.D., and Gilbert J.R. Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice. Neurobiol. Dis. 3 (1996) 229-245
233. Xu P.-T., Schmechel D., Qiu H.-L., Herbstreith M., Rothrock-Christian T., Eyster M., Roses A.D., and Gilbert J.R. Sialylated human apolipoprotein E (apoEs) is preferentially associated with neuron-enriched cultures from APOE transgenic mice. Neurobiol. Dis. 6 (1999) 63-75
234. Xu Q., Bernardo A., Walker D., Kanegawa T., Mahley R.W., and Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J. Neurosci. 26 (2006) 4985-4994
235. Yamauchi K., Tozuka M., Hidaka H., Nakabayashi T., Sugano M., Kondo Y., Nakagawara A., and Katsuyama T. Effect of apolipoprotein AII on the interaction of apolipoprotein E with beta-amyloid: some apo(E-AII) complexes inhibit the internalization of beta-amyloid in cultures of neuroblastoma cells. J. Neurosci. Res. 62 (2000) 608-614
236. Yamauchi K., Tozuka M., Hidaka H., Nakabayashi T., Sugano M., and Katsuyama T. Isoform-specific effect of apolipoprotein E on endocytosis of beta-amyloid in cultures of neuroblastoma cells. Ann. Clin. Lab. Sci. 32 (2002) 65-74
237. Yang D.S., Smith J.D., Zhou Z., Gandy S.E., and Martins R.N. Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J. Neurochem. 68 (1997) 721-725
238. Yang D.S., Small D.H., Seydel U., Smith J.D., Hallmayer J., Gandy S.E., and Martins R.N. Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience 90 (1999) 1217-1226
239. Ye S., Huang Y., Mullendorff K., Dong L., Giedt G., Meng E.C., Cohen F.E., Kuntz I.D., Weisgraber K.H., and Mahley R.W. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc. Natl. Acad. Sci. USA 102 (2005) 18700-18705
240. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57 (2008) 178-201
241. Zou F., Gopalraj R.K., Lok J., Zhu H., Ling I.F., Simpson J.F., Tucker H.M., Kelly J.F., Younkin S.G., Dickson D.W., et al. Sex-dependent Association of a Common Low Density Lipoprotein Receptor Polymorphism with RNA Splicing Efficiency in the Brain and Alzheimers Disease. Hum. Mol. Genet. 17 (2008) 929-935